Skip to main content

Rallybio Corporation (RLYB)

NASDAQ: RLYB · Delayed Price · USD
11.00 0.17 (1.57%)
Sep 21, 2021 4:00 PM EDT - Market closed
Market Cap343.20M
Revenue (ttm)n/a
Net Income (ttm)-35.84M
Shares Out31.20M
EPS (ttm)-1.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume142,220
Open10.84
Previous Close10.83
Day's Range10.05 - 11.53
52-Week Range10.05 - 25.78
Betan/a
AnalystsStrong Buy
Price Target30.00 (+172.7%)
Est. Earnings DateNov 15, 2021

About RLYB

Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry experts with a shared purpose and a track record of success in discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of patients suffering from severe and rare diseases. Since our launch in January 2018, we have acquired a portfolio of promising product candidates that consists of five programs, and we are focused on further expanding our portfolio with the goal of making a profound impact on the lives of eve...

IndustryBiotechnology
IPO DateJul 29, 2021
CEOMartin W. Mackay, Ph.D.
Employees28
Stock ExchangeNASDAQ
Ticker SymbolRLYB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Rallybio stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 172.73% from the latest price.

Price Target
$30.00
(172.73% upside)
Analyst Consensus: Strong Buy

News

Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights

NEW HAVEN, Conn.--(BUSINESS WIRE)---- $RLYB #FNAIT--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transfor...

1 week ago - Business Wire

Monday Afternoon Analyst Upgrades and Downgrades: Chesapeake Energy, Traeger and More

With the trading day more than halfway over, the broad markets had a roaring start to the week with the S&P 500 and Nasdaq hitting record intraday highs.

Other symbols:CHKCOOKCADLNUVLRSKD
4 weeks ago - 24/7 Wall Street

Andreas Halvorsen Gets a Healthy Dose of Rallybio

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed a stake in Rallybio Corp. ( RLYB , Financial) earlier this week, seeing a value opportunity in a newly public company.

1 month ago - GuruFocus

Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Pu...

NEW HAVEN, Conn.--(BUSINESS WIRE)-- #Rallybio--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming ...

1 month ago - Business Wire

Rallybio Corporation Announces Pricing of Initial Public Offering

Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disease...

1 month ago - Business Wire

Rallybio IPO Registration Document (S-1)

Rallybio Corporation has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC

Fierce15 winner Rallybio establishes proof-of-concept in phase 1/2 study for rare fetal bleeding disorder

2018 Fierce15 winner Rallybio has established proof-of-concept for an antibody treatment aiming to prevent a rare disease that causes a mother’s immune system to attack her fetus or newborn child’s plat...

2 months ago - FierceBiotech